Related Experiment Video

Updated: May 24, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence

Charlotte Lemech1, Jeffrey Infante, Hendrik-Tobias Arkenau

  • 1Sarah Cannon Research UK, London and University College London, London, UK.

Therapeutic Advances in Medical Oncology
|March 17, 2012
PubMed

Insights

Targeted therapies like BRAF and MEK inhibitors have transformed advanced cutaneous melanoma treatment, offering superior response rates compared to chemotherapy. Understanding resistance mechanisms is key for developing new combination therapies.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Advanced cutaneous melanoma historically presents a poor prognosis with limited therapeutic options.
  • The identification of the BRAF V600 mutation as a key oncogenic driver in melanoma has been pivotal.
  • The mitogen-activated protein kinase (MAPK) pathway plays a crucial role in melanoma tumor development.

Purpose of the Study:

  • To review the clinical efficacy of BRAF and MEK inhibitors in advanced cutaneous melanoma.
  • To discuss the mechanisms of resistance to MAPK pathway-targeted therapies.
  • To highlight the implications for future drug development and combination strategies.

Main Methods:

  • Review of phase I-III clinical trial results for BRAF and MEK inhibitors.
  • Analysis of published literature on melanoma tumorigenesis and resistance mechanisms.
  • Synthesis of data regarding treatment outcomes and adverse events.

Main Results:

  • Selective BRAF inhibitors and MEK inhibitors demonstrate significantly higher response rates than traditional chemotherapy.
  • These targeted agents have shifted the treatment paradigm for BRAF- V600-mutated melanoma.
  • Various resistance mechanisms, including those upstream, downstream, or bypassing the MAPK pathway, have been identified.

Conclusions:

  • BRAF and MEK inhibitors represent a major advancement in treating advanced cutaneous melanoma.
  • Understanding resistance pathways is crucial for designing effective combination therapies.
  • Further research into overcoming resistance will improve long-term patient outcomes.
Keywords:
BRAF V600EBRAF inhibitorMEK inhibitorcutaneous melanomaipilimumabresistancevemurafenib

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression11:02

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

Published on: August 3, 2011

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...